Psychedelics in

Psychiatry and

Psychotherapy (ISPPP)

Interdisciplinary Conference on

Psychedelic Research

Exclusive 1-day symposium for Dutch healthcare professionals

24 September 2020 | Online

What?

An international symposium featuring many of the world’s leading experts in psychedelic research and therapy.

For whom?

Psychiatrists, GZ psychologists, psychotherapists, clinical psychologists, addiction doctors, and other mental health professionals in the Netherlands.

Details

Where?

Online

When?

Thursday 24 September

09:00 – 16:30 CEST

Accreditation

Continuing (medical) education 9 points (FGzPt). 6 points (VVGN, KNMG, NVvP).

More information here.



There is a growing body of evidence suggesting that psychedelics can be used safely and effectively to treat mental disorders, including depression, PTSD, and substance use disorders.



During this one-day symposium, leading psychiatrists, psychotherapists, neuroscientists, and psychopharmacologists in the field of psychedelic-assisted therapies will share the latest scientific developments and insights into the therapeutic use of psychedelics, and discuss the future of treatment and research with MDMA, psilocybin, LSD and other compounds.



This state-of-the-art symposium will showcase the latest clinical evidence on psychedelics in the treatment of mental disorders and will facilitate in-depth interaction and discussion.



Chairs

Prof. dr. Eric Vermetten (LUMC)

Prof. dr. Robert Schoevers (UMCG)

Dr. Metten Somers (UMC Utrecht)

Prof. dr. Wim van den Brink (AUMC).


CME Credits

VVGN (Dutch Association for Addiction Medicine) 6 points

KNMG (Royal Dutch Medical Association) 6 points

FGzPt (Dutch Federation of Healthcare Psychologists and Psychotherapists) 9 points

NVvP (Dutch Association for Psychiatry) 6 points




Tickets

This is a separate symposium aimed to inform and educate healthcare professionals in the Netherlands. Attendees of ICPR 2020 don’t need to worry, as all speakers will also present during the three days of ICPR 2020.


Due to recent covid-related changes, we have decided to host the conference online and have reduced ticket prices accordingly. Registration fees are now €195.

For a surplus of €100, attendees will also gain access to all 3 conference days of the Interdisciplinary Conference on Psychedelic Research. Discounted tickets are available for AIOs, resident psychiatrists in GZ-psychologists in training, at €95.



CONFIRMED ISPPP SPEAKERS

Michelle Baker Jones
MICHELLE BAKER JONES

Imperial College London

Michael Mithoefer
MICHAEL MITHOEFER

Multidisciplinary Association for Psychedelic Studies

Matthew Johnson
MATTHEW JOHNSON

Johns Hopkins University

Katrin Preller
KATRIN PRELLER

University of Zurich

Elizabeth Nielson
ELIZABETH NIELSON

NYU; Columbia University

Mendel Kaelen
MENDEL KAELEN

Wavepaths

Ben Sessa
BEN SESSA

Imperial College London

Peter Gasser
PETER GASSER

Private Practice

Torsten Passie
TORSTEN PASSIE

Hannover Medical School

Some of the questions that will be discussed at ISPPP

  • What skills, competencies and knowledge do therapists need and how do we train them?
  • What do we know about the neuro-biological and psychological working mechanisms of these substances?
  • What is the role of treatment context, music, and integration sessions in establishing (long-term) clinical outcomes?
  • Can psychedelic-assisted treatments be integrated into conventional mental health care infrastructures?
  • Can we apply conventional psycho-therapeutic methods to psychedelic-assisted therapies or are novel methods needed?

PROGRAMME

This is the final programme for ISPPP. Time is in CET.

08:30 – 09:00

Registration

OPENING

TRACK 1

09:00 – 09:25

Introduction

Eric Vermetten, MD PhD

09:25 – 09:50

Music as Psychedelic Therapy

Mendel Kaelen, PhD

09:50 – 10:30

Psilocybin Treatment for Depression – Patient and Therapist Perspectives

Michelle Baker-Jones

Matt Jackson


COFFEE BREAK


TRACK 2

 11:00 – 11:25

Biological and psychological working mechanisms of psychedelics and entactogens

Katrin Preller, PhD

11:25 – 11:50

The development of psycholytic / psychedelic therapy

Peter Gasser, MD

11:50 – 12:15

Low-dose psycholytic therapy

Torsten Passie, MD PhD

12:15 – 13:00

Q&A with Peter Gasser, Torsten Passie, Mendel Kaelen and Katrin Preller


LUNCH


TRACK 3

14:00 – 14:25

MDMA-assisted Psychotherapy for Alcoholism

Ben Sessa, MD

14:25 – 14:50

Psychedelics as Behavior Change Agents

Matthew Johnson, PhD

14:50 – 15:15

MDMA-assisted Psychotherapy for PTSD – Update and Observations from Clinical Trials

Michael Mithoefer, MD


TEA BREAK


15:30 – 16:20

Panel discussion – therapist competencies & training

Eric Vermetten with Michael Mithoefer, Ros Watts, Elizabeth Nielson and Peter Gasser

CLOSING

NEWSLETTER

STAY IN TOUCH

Learn about new events and breakthroughs in the psychedelic scientific community.